癌症診斷聯合研究和許可協議（2018-2024）

Cancer Diagnostic Collaboration and Licensing Deals 2018-2024

出版日期: 2024年11月01日 | 出版商:

Current Partnering | 英文 450+ Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

本報告審查了癌症診斷合作和許可協議，詳細瞭解和分析了公司如何以及為何簽訂癌症診斷協議。

簡介
過去幾年的癌症診斷合約
最活躍的癌症診斷合約公司
癌症診斷合約：依合約類型
癌症診斷合約：依治療領域
癌症診斷合約：依行業分類
癌症診斷合約條款與條件
- 癌症診斷合約的總金額
- 癌症診斷合約預付款
- 癌症診斷合約的里程碑付款
- 癌症診斷特許權使用費

第3章主要癌症診斷合約

簡介
以價值排名最高的癌症診斷合約

第4章最活躍的癌症診斷合約公司

簡介
最活躍的癌症診斷合約公司
最活躍的癌症診斷合約公司簡介

第5章癌症診斷合約目錄

簡介
癌症診斷合約目錄

第 6 章癌症診斷合約：依技術類型

合約目錄
合約目錄 - 癌症診斷合約：依公司分類（A-Z）
合約目錄 - 癌症診斷合約：依合約類型
合約目錄 - 癌症診斷合約：依治療領域
合約類型的定義
關於生物製藥研究股份有限公司
當前合作夥伴
當前協議
Current Partnering 近期報告的標題

簡介目錄

Product Code: CP22013

Cancer Diagnostic Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the cancer diagnostic deals entered into by the world's leading biopharma companies.

Fully revised and updated, the report provides details of cancer diagnostic deals from 2018 to 2024.

The report provides a detailed understanding and analysis of how and why companies enter cancer diagnostic deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

The report includes collaboration, development, research and licensing deals.

This report contains a comprehensive listing of 702 cancer diagnostic deals announced since 2018 including financial terms where available including links to online deal records of actual cancer diagnostic partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of cancer diagnostic dealmaking.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in cancer diagnostic dealmaking since 2018.

Chapter 3 provides an overview of the leading cancer diagnostic deals since 2018. Deals are listed by headline value.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in cancer diagnostic dealmaking with a brief summary followed by a comprehensive listing of cancer diagnostic deals, as well as contract documents available in the public domain.

Chapter 5 provides a comprehensive and detailed review of cancer diagnostic deals signed and announced since Jan 2018, where a contract document is available in the public domain.

Chapter 6 provides a comprehensive and detailed review of cancer diagnostic partnering deals signed and announced since Jan 2018. The chapter is organized by specific cancer diagnostic technology type in focus.

The report also includes numerous table and figures that illustrate the trends and activities in cancer diagnostic deal making since 2018.

In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Cancer Diagnostic Collaboration and Licensing Deals provides the reader with the following key benefits:

Understand deal trends since 2018
Browse cancer diagnostic collaboration and licensing deals
Benchmark analysis - identify market value of transactions
Financials terms - upfront, milestone, royalties
Directory of deals by company A-Z, deal type and therapy area
Leading deals by value
Most active dealmakers
Identify assets and deal terms for each transaction
Access contract documents - insights into deal structures
Due diligence - assess suitability of your proposed deal terms for partner companies
Save hundreds of hours of research time

Report scope

Cancer Diagnostic Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of cancer diagnostic trends and structure of deals entered into by leading biopharma companies worldwide.

Cancer Diagnostic Collaboration and Licensing Deals includes:

Trends in cancer diagnostic dealmaking in the biopharma industry
Directory of cancer diagnostic deal records covering pharmaceutical and biotechnology
The leading cancer diagnostic deals by value
Most active cancer diagnostic licensing dealmakers
Cancer Diagnostic Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in cancer diagnostic dealmaking

2.1. Introduction
2.2. Cancer diagnostic deals over the years
2.3. Most active cancer diagnostic dealmakers
2.4. Cancer diagnostic deals by deal type
2.5. Cancer diagnostic deals by therapy area
2.6. Cancer diagnostic deals by industry sector
2.7. Deal terms for cancer diagnostic deals
- 2.7.1 Cancer diagnostic deals headline values
- 2.7.2 Cancer diagnostic deal upfront payments
- 2.7.3 Cancer diagnostic deal milestone payments
- 2.7.4 Cancer diagnostic royalty rates